(Q73280028)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Glucocorticoid-induced osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Kenneth G Saag

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

Endocrinology and Metabolism Clinics of North America

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

135-57, vii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone loss in response to long-term glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Corticosteroid osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Users of low-dose glucocorticoids have increased bone loss rates: A longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone mineral density in children with juvenile chronic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Generalised bone loss in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Osteoporosis in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Rheumatoid arthritis, corticosteroid therapy and hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Risk of vertebral fracture in women with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Osteoporosis in steroid-dependent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Inflammatory bowel disease and osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Osteoporosis in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Damage in systemic lupus erythematosus and its association with corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Rapid loss of vertebral mineral density after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Osteoporosis after organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Increased risk of fracture in patients receiving solid organ transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Osteoporosis after organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Determinants of axial bone loss in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Inhaled and oral corticosteroids: their effects on bone mineral density in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effects of inhaled glucocorticoids on bone density in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Inhaled corticosteroid use and bone-mineral density in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Use of inhaled corticosteroids and risk of fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Vertebral Fracture Risk With Long-term Corticosteroid Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Corticosteroids do not alter the threshold for vertebral fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Steroid-induced fractures and bone loss in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Use of oral corticosteroids and risk of fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

New developments in the pathogenesis and treatment of steroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Malabsorption of calcium in corticosteroid-induced osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Cortisol-induced suppression of plasma testosterone in normal adult males

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Reduction of serum testosterone levels during chronic glucocorticoid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Inhibition of Luteinizing Hormone Secretion Induced by Synthetic LRH by Long-term Treatment with Glucocorticoids in Human Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Management of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Recovery from steroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Calcium supplements in the prevention of steroid-induced osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Salmon calcitonin in the therapy of corticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Testosterone therapy in glucocorticoid-treated men

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Increased bone density in patients on steroids with etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Does growth hormone treatment prevent corticosteroid-induced osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Prevention of corticosteroid-induced osteoporosis: results of a patient survey

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900064-6

7 January 2021

10.1016/S0889-8529(02)00064-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699296%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference